tetano
Editor, Senior Moderator
NPJ Vaccines
. 2022 Jun 29;7(1):68.
doi: 10.1038/s41541-022-00498-6.
A chimeric thermostable M2e and H3 stalk-based universal influenza A virus vaccine
Jeeva Subbiah[SUP] 1 [/SUP], Judy Oh[SUP] 1 [/SUP], Ki-Hye Kim[SUP] 1 [/SUP], Chong-Hyun Shin[SUP] 1 [/SUP], Bo Ryoung Park[SUP] 1 [/SUP], Noopur Bhatnagar[SUP] 1 [/SUP], Baik-Lin Seong[SUP] 2 3 [/SUP], Bao-Zhong Wang[SUP] 1 [/SUP], Sang-Moo Kang[SUP] 4 [/SUP]
Affiliations
Abstract
We developed a new chimeric M2e and H3 hemagglutinin (HA) stalk protein vaccine (M2e-H3 stalk) by genetic engineering of modified H3 stalk domain conjugated with conserved M2e epitopes to overcome the drawbacks of low efficacy by monomeric domain-based universal vaccines. M2e-H3 stalk protein expressed and purified from Escherichia coli was thermostable, displaying native-like antigenic epitopes recognized by antisera of different HA subtype proteins and influenza A virus infections. Adjuvanted M2e-H3 stalk vaccination induced M2e and stalk-specific IgG antibodies recognizing viral antigens on virus particles and on the infected cell surface, CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T-cell responses, and antibody-dependent cytotoxic cell surrogate activity in mice. M2e-H3 stalk was found to confer protection against heterologous and heterosubtypic cross-group subtype viruses (H1N1, H5N1, H9N2, H3N2, H7N9) at similar levels in adult and aged mice. These results provide evidence that M2e-H3 stalk chimeric proteins can be developed as a universal influenza A virus vaccine candidate for young and aged populations.
. 2022 Jun 29;7(1):68.
doi: 10.1038/s41541-022-00498-6.
A chimeric thermostable M2e and H3 stalk-based universal influenza A virus vaccine
Jeeva Subbiah[SUP] 1 [/SUP], Judy Oh[SUP] 1 [/SUP], Ki-Hye Kim[SUP] 1 [/SUP], Chong-Hyun Shin[SUP] 1 [/SUP], Bo Ryoung Park[SUP] 1 [/SUP], Noopur Bhatnagar[SUP] 1 [/SUP], Baik-Lin Seong[SUP] 2 3 [/SUP], Bao-Zhong Wang[SUP] 1 [/SUP], Sang-Moo Kang[SUP] 4 [/SUP]
Affiliations
- PMID: 35768475
- DOI: 10.1038/s41541-022-00498-6
Abstract
We developed a new chimeric M2e and H3 hemagglutinin (HA) stalk protein vaccine (M2e-H3 stalk) by genetic engineering of modified H3 stalk domain conjugated with conserved M2e epitopes to overcome the drawbacks of low efficacy by monomeric domain-based universal vaccines. M2e-H3 stalk protein expressed and purified from Escherichia coli was thermostable, displaying native-like antigenic epitopes recognized by antisera of different HA subtype proteins and influenza A virus infections. Adjuvanted M2e-H3 stalk vaccination induced M2e and stalk-specific IgG antibodies recognizing viral antigens on virus particles and on the infected cell surface, CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T-cell responses, and antibody-dependent cytotoxic cell surrogate activity in mice. M2e-H3 stalk was found to confer protection against heterologous and heterosubtypic cross-group subtype viruses (H1N1, H5N1, H9N2, H3N2, H7N9) at similar levels in adult and aged mice. These results provide evidence that M2e-H3 stalk chimeric proteins can be developed as a universal influenza A virus vaccine candidate for young and aged populations.